Clinical trial
Vinorelbine and XR9576 to Treat Cancer
NCT00001944 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001944 |
|---|---|
| Title | Vinorelbine and XR9576 to Treat Cancer |
| Official title | A Clinical Trial of the P-Glycoprotein Antagonist, XR9576, in Combination With Vinorelbine in Patients With Cancer: Analysis of the Interaction Between XR9576 and Vinorelbine |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer, Cancer, Lung Cancer, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Vinorelbine, XR9576 |
| Enrollment | 30 |
| Start date | Dec 1, 1999 |
| Completion | Jun 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: